NCT03860597View on ClinicalTrials.gov

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
SchizophreniaSchizo Affective DisorderSchizoaffective DisorderHealthy
Interventions
DRUG

Memantine

To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.

DRUG

Placebos

To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.

Trial Locations (1)

92103

Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT03860597 - Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia | Biotech Hunter | Biotech Hunter